Research Triangle Park, North Carolina -- Medical device technology company Entegrion has received $2.8 million in new equity venture capital investment, according to an SEC regulatory filing.
Entegrion is focused on improving the safety and availability of blood supply around the world.
The company provides a variety of technologies to "overcome limitations in storage, safety and availability of blood-derived products while preserving their functionality."
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of 49 investors participated in the offering.
Entegrion is still seeking $675,000 in additional financing, according to the filing.